TY - JOUR
T1 - Active-Site Flexibility and Substrate Specificity in a Bacterial Virulence Factor
T2 - Crystallographic Snapshots of an Epoxide Hydrolase
AU - Hvorecny, Kelli L.
AU - Bahl, Christopher D.
AU - Kitamura, Seiya
AU - Lee, Kin Sing Stephen
AU - Hammock, Bruce D.
AU - Morisseau, Christophe
AU - Madden, Dean R.
N1 - Funding Information:
We would like to thank Dr. Vivian Stojanoff, Dr. Jean Jakonic, and Edwin Lazo at Beamline X6A of NSLS at BNL, Dr. Clyde Smith and the staff of Beamlines 14-1 and 9-3 of SSRL at SLAC, and Drs. Diane Bryant and Corie Ralston at Beamline 5.0.3 of ALS at LBNL for help with data collection. We would also like to thank Drs. Scott Gerber, George O'Toole, and Peter Jacobi for helpful discussions. This work was supported by the NIH (R01AI091699, P20GM113132, P30GM106394, U24DK097154, T32GM008704, R01ES002710, P42ES004699, and K99ES024806/R00ES024806), the Cystic Fibrosis Foundation (STANTO19R0), and the Munck-Pfefferkorn Fund. S.K. was financially supported by Japan Student Services Organization. Beamline access was supported in part by the NIH (GM-0080, P41-GM111244, P41-GM103393) and the DOE (DE-SC0012704, DE-AC02-76SF00515). D.R.M., C.D.B., C.M., and B.D.H are the co-inventors of Cif inhibitor intellectual property held by Dartmouth College. B.D.H is a founder and CEO of EicOsis, a company that develops sEH inhibitors for treatment of neuropathic pain.
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/5/2
Y1 - 2017/5/2
N2 - Pseudomonas aeruginosa secretes an epoxide hydrolase with catalytic activity that triggers degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and perturbs other host defense networks. Targets of this CFTR inhibitory factor (Cif) are largely unknown, but include an epoxy-fatty acid. In this class of signaling molecules, chirality can be an important determinant of physiological output and potency. Here we explore the active-site chemistry of this two-step α/β-hydrolase and its implications for an emerging class of virulence enzymes. In combination with hydrolysis data, crystal structures of 15 trapped hydroxyalkyl-enzyme intermediates reveal the stereochemical basis of Cif's substrate specificity, as well as its regioisomeric and enantiomeric preferences. The structures also reveal distinct sets of conformational changes that enable the active site to expand dramatically in two directions, accommodating a surprising array of potential physiological epoxide targets. These new substrates may contribute to Cif's diverse effects in vivo, and thus to the success of P. aeruginosa and other pathogens during infection.
AB - Pseudomonas aeruginosa secretes an epoxide hydrolase with catalytic activity that triggers degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and perturbs other host defense networks. Targets of this CFTR inhibitory factor (Cif) are largely unknown, but include an epoxy-fatty acid. In this class of signaling molecules, chirality can be an important determinant of physiological output and potency. Here we explore the active-site chemistry of this two-step α/β-hydrolase and its implications for an emerging class of virulence enzymes. In combination with hydrolysis data, crystal structures of 15 trapped hydroxyalkyl-enzyme intermediates reveal the stereochemical basis of Cif's substrate specificity, as well as its regioisomeric and enantiomeric preferences. The structures also reveal distinct sets of conformational changes that enable the active site to expand dramatically in two directions, accommodating a surprising array of potential physiological epoxide targets. These new substrates may contribute to Cif's diverse effects in vivo, and thus to the success of P. aeruginosa and other pathogens during infection.
KW - Pseudomonas aeruginosa
KW - X-ray crystallography
KW - enzyme stereospecificity
KW - epoxide hydrolase
KW - epoxy-fatty acids
KW - hydroxyalkyl-enzyme intermediate
KW - structure-function relationships
KW - virulence factor
UR - http://www.scopus.com/inward/record.url?scp=85017104673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017104673&partnerID=8YFLogxK
U2 - 10.1016/j.str.2017.03.002
DO - 10.1016/j.str.2017.03.002
M3 - Article
C2 - 28392259
AN - SCOPUS:85017104673
SN - 0969-2126
VL - 25
SP - 697-707.e4
JO - Structure
JF - Structure
IS - 5
ER -